Nexalin Tech Stock Price, News & Analysis

Nexalin Technology (Nasdaq: NXL) has announced an exclusive live investor webinar scheduled for January 23, 2025, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature CEO Mark White discussing the company's non-invasive frequency-based deep brain stimulation device and progress on their new Gen-3 HALO™ Clarity & Virtual Clinic model.

The company's solutions have demonstrated clinically meaningful improvements in treating insomnia, PTSD, and traumatic brain injuries. These conditions affect millions of people and currently have effective treatments. The market for these solutions is projected to reach $537 billion by 2030. The webinar will include a live Q&A session, and investors can pre-submit questions or ask them during the event.

Nexalin Technology (NXL) has released a shareholder letter highlighting achievements and 2025 outlook. The company's Deep Intracranial Frequency Stimulation (DIFS) technology has shown significant results in mental health treatment, achieving a 65% response rate in depression trials. Their Gen-3 Halo headset delivers a proprietary 15 mA waveform that's 5-10 times more powerful than existing devices.

Key developments include: launching a virtual clinic with AI integration, conducting 29 IRB-approved clinical trials, and receiving regulatory approvals in China, Brazil, and Oman. The company is pursuing CE Mark approval for European market entry in 2025. Research shows promising results in Alzheimer's treatment, with increased brain activity in memory-related areas. The company is also focusing on PTSD and TBI research through collaborations with UC San Diego and the VA.

With the neuromodulation market projected to reach $11 billion by 2028, Nexalin aims to expand its global presence while advancing research in mood disorders, Alzheimer's, and addiction treatment.

Nexalin Technology (NXL) has completed Phase 1 of its proprietary virtual clinic, incorporating AI components for Electronic Data Capture (EDC) and Patient Monitoring System (PMS). The virtual platform is designed to enable clinical trials and treatments to be conducted remotely from patients' homes while providing real-time data to physicians.

The system will support Nexalin's Generation 3 Halo Device, a non-invasive headset that delivers 15mAmp deep frequency stimulation to treat mental health conditions including depression, insomnia, Alzheimer's disease, and addiction. The Halo device requires FDA clearance and physician prescription.

The EDC platform enables real-time data collection during trials through a smartphone application, while the PMS allows clinical teams to monitor patient progress and make treatment adjustments. The virtual clinic includes telemedicine features for direct patient-physician communication.

Nexalin Technology (NXL) announces validation of its Deep Intracranial Frequency Stimulation (DIFS) technology in a new peer-reviewed editorial published in Psychotherapy and Psychosomatics. The company's 15mA DIFS technology demonstrates superior deep brain penetration compared to traditional neurostimulation methods, effectively reaching critical areas like the hippocampus, amygdala, and insula. The neuromodulation market is projected to reach $11.0 billion by 2028.

The publication validates DIFS's ability to non-invasively treat psychiatric conditions like major depressive disorder and chronic insomnia, offering a safer alternative to invasive procedures while providing tailored neuromodulation for different conditions.

Nexalin Technology (Nasdaq: NXL) released a shareholder letter highlighting recent achievements in their Deep Intracranial Frequency Stimulation (DIFS) technology. The company reported two significant Alzheimer's research studies in October showing improvements in memory and cognitive function. They secured a key patent for frequency-based deep brain stimulation in treating Alzheimer's and dementia. Additionally, their DIFS technology demonstrated positive results in treating Major Depressive Disorder (MDD). The company announced a clinical trial collaboration with UC San Diego and San Diego VA to study their Gen-3 Halo headset for mild Traumatic Brain Injury treatment. Nexalin also received regulatory approval in Brazil for their Gen-2 15 mA neurostimulation device.

Nexalin Technology (Nasdaq: NXL) announces an upcoming investor webinar scheduled for November 5th, 2024, at 4:15 p.m. ET. CEO Mark White will present the company's progress on their non-invasive deep brain stimulation device and the new Gen-3 HALO™ Clarity & Virtual Clinic model. The presentation will highlight clinical data showing improvements in treating insomnia, PTSD, and traumatic brain injuries. The company operates in a market projected to reach $537 billion by 2030. The event includes a live Q&A session and is free to attend with registration.

Nexalin Technology (Nasdaq: NXL) has received notice from Nasdaq confirming its regained compliance with the minimum bid price requirement under Rule 5550(a)(2). The notification was received on October 31, 2024. CEO Mark White emphasized this achievement as a significant milestone in the company's mission to develop non-invasive neurostimulation treatments, highlighting its importance for shareholder value and investor visibility as the company progresses with clinical research and global regulatory approvals.

Nexalin Technology (NXL) published a landmark study in the Journal of Alzheimer's Disease demonstrating the effectiveness of their Deep Intracranial Frequency Stimulation (DIFS) technology. The study, involving 46 patients over three weeks, showed significant improvements in brain function and cognitive performance in Alzheimer's patients. Key findings include increased neuronal activity, enhanced brain connectivity, improved blood flow, and sustained cognitive benefits over a three-month follow-up period. The treatment proved safe and well-tolerated, with no serious side effects reported. The study validates DIFS as a potential non-pharmacological treatment option for Alzheimer's disease, which affects over 50 million people globally.

Nexalin Technology (NXL) has announced plans for a new clinical trial in collaboration with UC San Diego and San Diego VA. The study will evaluate the effectiveness of Nexalin's Gen-3 Halo headset in treating veterans with mild Traumatic Brain Injury (mTBI) using a virtual clinic model. This innovative approach allows patients to receive treatment at home, potentially expanding access to care.

The trial builds on positive results from a previous study using Nexalin's Gen-2 device, which showed significant improvements in MEG signals and pain reduction for mTBI patients. The Gen-3 Halo headset incorporates Nexalin's proprietary Deep Intracranial Frequency Stimulation (DIFS®) technology with an advanced 15 milliamp waveform.

The study will recruit two groups: one receiving treatment with the Nexalin Gen-3 Halo headset and another using a sham device for comparison. It aims to assess changes in brain activity and correlate them with improvements in post-concussion symptoms and neuropsychological test performance.